Back to search

France· FR:66597770

AMBRISENTAN EG 5 mg, comprimé pelliculé

A ambrisentan product containing ambrisentan, registered in France by EG LABO - LABORATOIRES EUROGENERICS. The same ATC class is registered in 18 of our 19 countries.

ATC C02KX02

Checked against Base de données publique des médicaments — BDPM (France) on

Informational only — not a medical device.

SOURCE REGISTER · FRBase de données publique des médicament…normalisedAMBRISENTAN EG 5 mg, comprimé pellicu…ATCC02KX02REGISTER NO.FR:66597770PACKS LISTED1CHECKEDSeptember 12, 2026

Where it is registered

Ambrisentan is registered in 18 of 19 countries.

Countries holding a registration under ATC C02KX02 (ambrisentan), each read from that country’s own register.

  • This record: France, from Base de données publique des médicaments — BDPM (France)
  • 10 of them publish a price we can compare per daily dose

Ambrisentan · ATC C02KX02

18 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Germany
  • Icelandprice
  • Ireland
  • Italyprice
  • Japan
  • Netherlands
  • Norwayprice
  • Polandprice
  • Sweden
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of ambrisentan costs, country by country.

Normalised to the WHO defined daily dose (7.5 mg), so markets compare like for like.

  • 1 market with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown

Ambrisentan · price per daily dose (7.5 mg)

USD · FX 28 Sept 2026

  • CH Switzerland$54.19
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

Base de données publique des médicaments — BDPM (France)
Active substance
AMBRISENTAN
Manufacturer
EG LABO - LABORATOIRES EUROGENERICS
Country
France (FR)
ATC code
C02KX02
ATC class
Ambrisentan
Defined daily dose
7.5 mg, O
Reimbursed
No
Source register
Base de données publique des médicaments — BDPM (France)
Last checked
September 12, 2026

Packs & prices · 1

  • cip13
    3400930196106
    30 plaquette(s) PVC PVDC aluminium de 1 comprimé(s)

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

155 interactions on record for ambrisentan.

Graded by severity as the source publishes them — 5 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Ambrisentan · interactions on record

155 records

  • 5 severe
  • 71 moderate
  • 12 minor
  • 67 info

Most severe, free to view

  • LeflunomidL04AA13severe
  • TeriflunomidL04AA31severe
  • CiclosporinL04AD01severe
  • LeflunomideL04AK01severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Ambrisentan in 16 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All ambrisentan products

Authorised across Europe · EMA

The same active substance is authorised in 26 EEA countries. Names it is sold under:

  • Austria · Ambrisentan Accord, Ambrisentan Aop
  • Belgium · Ambrisentan Accord, Ambrisentan Sandoz
  • Bulgaria · Aмбрисентан Aкорд, Амбрисентан Зентива
  • Cyprus · Ambrisentan Msn, Ambrisentan Sapiens
  • Czechia · Ambrisentan Accord, Ambrisentan Sandoz
  • Germany · Ambripuren, Ambrisentan
  • Denmark · Ambrisentan "sandoz", Ambrisentan Accord
  • Estonia · Ambrisentan Inteli, Ambrisentan Norameda
  • Spain · Ambrisentan Accord, Ambrisentán Aurovitas
  • Finland · Ambrisentan Accord
  • United Kingdom (Northern Ireland) · Ambrisentan Accord, Ambrisentan Axunio
  • Greece · Ambicipen, Ambrisentan Accord
  • Croatia · Ambrisentan Accord
  • Hungary · Ambrisentan Azr
  • Ireland · Ambrisentan Accord
  • Iceland · Ambrisentan Viatris, Volibris
  • Italy · Ambrisentan Accord, Ambrisentan Medac
  • Liechtenstein · Ambrisentan Viatris, Volibris
  • Lithuania · Ambrisentan Aop, Ambrisentan Inteli
  • Latvia · Ambrisentan Inteli, Ambrisentan Norameda
  • Netherlands · Ambrisentan Accord, Ambrisentan Aop
  • Norway · Ambrisentan Accord, Ambrisentan Viatris
  • Portugal · Ambrisentano Accord, Ambrisentano Generis
  • Sweden · Ambrisentan Accord, Ambrisentan Bluefish
  • Slovenia · Ambrisentan Accord
  • Slovakia · Ambrisentan Aop

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/b4977f2c-60fd-4add-a97c-f90399d70efe
GET /v1/drugs/b4977f2c-60fd-4add-a97c-f90399d70efe?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "cis": "66597770",
  "date_amm": "2019-12-30",
  "type_amm": "Procédure décentralisée",
  "numero_ue": null,
  "substance": "AMBRISENTAN",
  "atc_source": "fr_atc_restore_2026-09-06",
  "statut_amm": "Autorisation abrogée",
  "statut_bdm": "Warning disponibilité",
  "forme_pharmaceutique": "comprimé pelliculé",
  "voies_administration": "orale",
  "etat_commercialisation": "Non commercialisée",
  "surveillance_renforcee": "Non"
}

See everything about ambrisentan.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.